ArticleFrontiers in immunology2026

A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus nivolumab.

Baylor Akhavan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.